Half Year Results 

Silence Therapeutics gets funding boost

Silence Therapeutics gets funding boost

Silence Therapeutics' (SLN) RNA interference (RNAi) collaboration with specialty pharmaceuticals manufacturer Mallinckrodt agreed in July should be "game-changing", according to chief executive David Horn Solomon. The deal provides the company with funds to continue to finance its research and development spending, with a $20m (£16.1m) upfront payment, $10m research and development payment, and a $5m equity investment with just over 5.06m shares purchased. Crucially, this brought the company’s cash balance to £36m at the end of August. 

To continue reading, subscribe today

and enjoy unlimited access to the following:

  • Tips of the Week
  • Funds coverage
  • Weekly features on big investment themes
  • Trading ideas
  • Comprehensive companies coverage
  • Economic analysis
Subscribe
Subscribe to Investors Chronicle

Subscribe today

Full access for just £3.37 a week:

• Tips and recommendations - to beat the market 
• Portfolio clinic & Mr Bearbull - build a well-planned portfolio 
• Expert tools - track and manage investments effortlessly
• Plus free delivery to your home or office

Subscribe Now